Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
about
Epigenetics of colorectal cancerA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersBeyond hypomethylating agents failure in patients with myelodysplastic syndromesNew strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practiceEpigenome-based personalized medicine in human cancerManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura.Current therapy of myelodysplastic syndromesThere's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematologyClinical utility of lenalidomide in the treatment of myelodysplastic syndromesPlatelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPExpanding role of lenalidomide in hematologic malignanciesConcise drug review: azacitidine and decitabineSequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Hypomethylating agents after allogeneic blood stem cell transplantation.Review of therapeutic options and the management of patients with myelodysplastic syndromes.5-Azacytidine for the treatment of myelodysplastic syndromes.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Update on the pharmacotherapy for myelodysplastic syndromes.Hematopoietic Cell Transplantation for Older Patients with MDS.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.DNA Hypomethylating Drugs in Cancer Therapy.Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
P2860
Q24598045-B44427F1-3EE3-416E-8F5B-3525F52F6490Q26743743-B7EA1BE8-1896-4A87-91B1-0BF7F0CCE30CQ26827079-655CD477-A707-4642-BF43-B62A977C5193Q27016511-36D97647-A046-401D-B601-BA213AC9F73DQ28083951-B38EEA56-1472-4039-BCAC-3B3A1FE52FACQ30235355-B555B05C-2783-4385-96A3-34C9388C584AQ30245476-BF278566-62DA-4746-B183-EF48D030B778Q33434768-5B663B0F-7783-4042-A791-328496EC665EQ33435162-EBE7961A-2C82-4AC7-A1BB-B32D01DF42D6Q34013796-977F9A14-55F1-4C72-971A-2992F622806EQ34049017-119B2B7E-D92A-4FEF-9F4B-B96DA7DF2E4CQ34342944-D5535872-BFF9-41EB-94EC-B5D71AB1B918Q34350209-8DFA9F49-E262-4309-8DEC-75F116E1DF3FQ34395179-9F461C7F-4BD6-4190-9D00-EE7DD895AD64Q34783754-A66AB91B-C11E-452D-B538-AB877655546AQ34986462-92DBC04C-DBB2-45E8-B281-B86C708B476BQ35592305-D4971A24-FD27-45B3-B001-CA09C3CE5968Q36871721-B4735675-B041-417B-80E4-5250E488FAB3Q37074311-889C14C2-1919-44C3-950C-EC50EF840384Q37216367-A869C3A2-9428-4688-88DD-AD854513D13DQ37531039-591CB59B-FF7B-4081-9462-F7C8AB3FC1DCQ38095121-8A6451A0-80A4-473F-AF80-34B457285E67Q38102062-3942D41D-C7E8-4950-98C7-1BAF03A9CCA0Q38110935-0267B9DC-D5BF-4D28-8329-F6249824E074Q38115584-0F44CA75-3EC7-475C-8691-2CA84FBB6184Q38172875-EC846BF2-F51B-49D0-86C6-40E582A54C58Q38195796-902044F9-4B40-4657-8CB3-D6582D75E43FQ38233492-CEF2AE34-6C3F-4F99-B6A3-D3DE448B434BQ38235662-FCB85A60-6246-4F9F-BB45-F5C85A341144Q38252578-07BCFCF2-83A5-407C-B3BA-ADD4F699C734Q38537883-5B032735-5BF3-4F45-AE27-89A23ADE16ECQ38540859-65AE44C3-778A-4E2F-A6FA-63F4186ECEEEQ38570399-DFB5977C-C4C5-4E01-A70F-0F8C8F36D6C6Q38678113-DCBD23FE-BDC5-4B2C-860A-D2217B0AA2DCQ38758162-34F64DA7-579E-4E56-9F01-99DC8668BD80Q38961023-E4F579B9-B17E-402E-AA6D-C2376F0D4CAAQ38979940-4330DEF3-A434-4C6E-9EE8-744A31B705EAQ39064474-1F5DA09D-62CA-47C8-9A1F-D3D27708B279Q39240258-98A714D4-0B4C-4419-B831-56904D5563FFQ40139200-3A75687B-511B-4A40-818A-B6772C181EE4
P2860
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@ast
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@en
type
label
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@ast
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@en
prefLabel
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@ast
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@en
P2093
P2860
P1433
P1476
Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.
@en
P2093
Alan F List
Ali Tabarroki
Andres Jerez
Anjali S Advani
David Cuthbertson
Hideki Makishima
Jaroslaw P Maciejewski
Jeffrey Lancet
Jennifer Paleveda
Joyce Juersivich
P2860
P304
P356
10.1182/BLOOD-2012-06-434639
P407
P577
2012-08-22T00:00:00Z